Explore Our Resource Library

Several inhibitors of androgen receptor (AR) function are approved for prostate cancer treatment, and their impact on gene transcription has been described. However, the ensuing effects at the protein level are far less well understood. We focused on the AR signaling inhibitor darolutamide and confirmed its strong AR binding and antagonistic activity using the high throughput cellular thermal shift assay (CETSA HT). Then, we generated comprehensive, quantitative proteomic data from the androgen-sensitive prostate cancer cell line VCaP and compared them to transcriptomic data. Following...

DNA-binding proteins are promising therapeutic targets but are notoriously difficult to drug. Here, we evaluate a...

Novel treatment options for metastatic colorectal cancer (CRC) are urgently needed to improve patient outcome. Here, we...

We have used a mass spectrometry-based proteomic approach to compile an atlas of the thermal stability of 48,000...

Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15–20 months under...

Background & aims: Antibiotic (ABx) therapy is associated with increased risk for Crohn's disease but underlying...

Genome‐, transcriptome‐ and proteome‐wide measurements provide insights into how biological systems are regulated....

Despite their importance in determining protein abundance, a comprehensive catalogue of sequence features controlling...

Citrullination is a posttranslational modification of arginine catalyzed by five peptidylarginine deiminases (PADs) in...

The pig is one of the earliest domesticated animals in the history of human civilization and represents one of the most...